AtriCure (NSDQ:ATRC) announced today that the FDA approved its EPi-Sense system for treating long-standing persistent atrial fibrillation (Afib). Mason, Ohio-based AtriCure’s EPi-Sense system demonstrated superiority in the Hybrid AF therapy arm compared to endocardial catheter ablation alone in the Converge clinical trial, according to a news release. AtriCure’s Hybrid AF therapy is a minimally invasive […]
atricure
AtriCure beats the Street in Q1 results
AtriCure (NASDAQ:ATRC) posted first-quarter results today that beat the consensus forecast on Wall Street. The Mason, Ohio-based company reported losses of -$16.9 million, or -38¢ per share, on sales of $59.3 million for the three months ended March 31, for a sales growth of 11.37% compared with Q1 2020. Adjusted to exclude one-time items, earnings per […]
